Cognition Therapeutics, Inc. (CGTX)

In July 2025, the company had a key End of Phase 2 meeting with the FDA and released positive Phase 2 data from the SHIMMER study in DLB, causing the stock to jump, but it later plunged. In August 2025, Cognition Therapeutics regained compliance with NASDAQ's minimum bid price rule and completed a $30 million registered direct offering. In September 2025, the stock rose 12% on a $2.14 million grant from NIH. In November 2025, the Phase 2 'START' study for zervimesine completed enrollment. In December 2025, Cognition Therapeutics reached full enrollment in its Expanded Access Program and presented its Phase 3 plan at the CTAD Conference, also filing a follow-on equity offering of $75 million. In January 2026, Cognition Therapeutics published Phase 2 clinical results showing zervimesine's potential to slow the progression of Dementia with Lewy Bodies. The share price as of January 9, 2026, was $1.41, representing a 90.51% increase from $0.74 on January 13, 2025.

As a clinical-stage biopharmaceutical company, Cognition Therapeutics, Inc. does not have commercialized products or services subject to traditional consumer demand seasonality. The company's revenue is primarily derived from non-dilutive government grants and capital raised through equity offerings, making demand seasonality not a relevant factor in its business model.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. Their lead product candidate, zervimesine, is in Phase 2 clinical trials for Alzheimer's disease and dementia with Lewy bodies. The company's financial engine relies on government grants and equity offerings.

Cognition Therapeutics, Inc. is headquartered in Purchase, New York, and its operations are primarily based in the United States. The company was originally established in Pittsburgh in 2007.

Cognition Therapeutics, Inc. generally holds a positive reputation among analysts, with a consensus rating of "Moderate Buy" or "Strong Buy". The company's mission is driven by the human cost of neurodegenerative diseases, aiming to deliver a new class of oral, disease-modifying treatments with a patient-centric focus, contributing positively to its reputation within the scientific and medical communities.

The ownership structure of Cognition Therapeutics, Inc. includes institutional, insider, and retail investors. Institutional investors hold approximately 18.45% to 43.35% of the stock, with major shareholders including BIOS Capital Management, LP, and Vanguard Group Inc. Insiders hold approximately 14.40% to 16.10% of the stock, with Aaron Gl Fletcher being the largest individual shareholder. Retail investors hold a significant portion, with some sources indicating approximately 62.55% of the stock.